WO2000040205A3 - Sustained release formulation with reduced moisture sensitivity - Google Patents
Sustained release formulation with reduced moisture sensitivity Download PDFInfo
- Publication number
- WO2000040205A3 WO2000040205A3 PCT/US2000/000088 US0000088W WO0040205A3 WO 2000040205 A3 WO2000040205 A3 WO 2000040205A3 US 0000088 W US0000088 W US 0000088W WO 0040205 A3 WO0040205 A3 WO 0040205A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained release
- release formulation
- ingestible
- reduced moisture
- moisture sensitivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU34691/00A AU3469100A (en) | 1999-01-05 | 2000-01-04 | Sustained release formulation with reduced moisture sensitivity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22579599A | 1999-01-05 | 1999-01-05 | |
US09/225,795 | 1999-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000040205A2 WO2000040205A2 (en) | 2000-07-13 |
WO2000040205A3 true WO2000040205A3 (en) | 2000-09-28 |
Family
ID=22846274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/000088 WO2000040205A2 (en) | 1999-01-05 | 2000-01-04 | Sustained release formulation with reduced moisture sensitivity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3469100A (en) |
WO (1) | WO2000040205A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20050100608A1 (en) * | 2003-02-21 | 2005-05-12 | Watson Pharmaceuticals, Inc. | Testosterone oral dosage formulations and associated methods |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032049A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
FR2887455B1 (en) * | 2005-06-28 | 2007-08-10 | Sanofi Aventis Sa | FORMULATION WITH PROLONGED RELEASE OF ACTIVE MEDICINAL PRINCIPLES |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
RU2015138422A (en) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM |
CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
PL2611426T3 (en) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
EP2736497B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
MX362357B (en) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AR096439A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES |
WO2014191397A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
EA032465B1 (en) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof |
CN105934241B (en) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | Preparation of powdered pharmaceutical composition by cryogenic grinding |
JP2017518980A (en) | 2014-05-12 | 2017-07-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Anti-modification immediate release capsule formulation containing tapentadol |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US5591452A (en) * | 1993-05-10 | 1997-01-07 | Euro-Celtique, S.A. | Controlled release formulation |
US5601842A (en) * | 1993-09-03 | 1997-02-11 | Gruenenthal Gmbh | Sustained release drug formulation containing a tramadol salt |
-
2000
- 2000-01-04 AU AU34691/00A patent/AU3469100A/en not_active Abandoned
- 2000-01-04 WO PCT/US2000/000088 patent/WO2000040205A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US5591452A (en) * | 1993-05-10 | 1997-01-07 | Euro-Celtique, S.A. | Controlled release formulation |
US5601842A (en) * | 1993-09-03 | 1997-02-11 | Gruenenthal Gmbh | Sustained release drug formulation containing a tramadol salt |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
Also Published As
Publication number | Publication date |
---|---|
AU3469100A (en) | 2000-07-24 |
WO2000040205A2 (en) | 2000-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000040205A3 (en) | Sustained release formulation with reduced moisture sensitivity | |
GEP20064022B (en) | Pharmaceutical formulations comprising oxycodone and naloxone | |
WO2002026210A3 (en) | Proton pump inhibitor formulation | |
DE60028754D1 (en) | SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN | |
EP1251864A4 (en) | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release | |
WO2001032596A8 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
TWI235068B (en) | Sustained-release pharmaceutical composition | |
CA2333869A1 (en) | Mousse composition | |
WO2000045792A8 (en) | Hydrogel particle formulations | |
SG64993G (en) | Slow-release pharmaceutical composition | |
CA2457361A1 (en) | Opioid agonist formulations with releasable and sequestered antagonist | |
EP1337249A4 (en) | Compositions and methods for administration of pharmacologically active compounds | |
WO2000041681A3 (en) | MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST | |
CA2416403A1 (en) | A medicinal aerosol formulation | |
WO2006035417A3 (en) | Dihydropyrimidine microcapsule - formulations | |
CA2339765A1 (en) | Compounds and compositions for delivering active agents | |
WO2001035941A3 (en) | Novel composition based on a thiazolidinedione and metformin and use | |
WO2002008217A3 (en) | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | |
CA2360220A1 (en) | Oxadiazole compounds and compositions for delivering active agents | |
CA2352915A1 (en) | Pharmaceutical compositions containing mupirocin | |
AR099437A2 (en) | MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS | |
HK1040920A1 (en) | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent. | |
IS7394A (en) | Stable drug formulations | |
AU1650401A (en) | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | |
CA2216277A1 (en) | Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |